Literature DB >> 12220369

Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly.

David Blackburn1, Janet Hux, Muhammad Mamdani.   

Abstract

We conducted a population-based cohort study using administrative databases to quantify the association between oral and inhaled corticosteroid use and onset of diabetes mellitus in the elderly. Proton pump inhibitor (PPI) users were used as a control group. Relative to PPI users (N = 53,845), oral corticosteroid users (N = 31,864) were more likely to develop diabetes (adjusted rate ratio [aRR], 2.31; 95% confidence interval [95% CI], 2.11 to 2.54); however, inhaled corticosteroid users (N = 38,441) were not (aRR, 1.03; 95% CI, 0.93 to 1.14). The estimated number needed to harm for continuous use of oral corticosteroids relative to PPIs over 1, 2, and 3 years of use were 41, 23, and 16, respectively.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220369      PMCID: PMC1495107          DOI: 10.1046/j.1525-1497.2002.10649.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  12 in total

1.  Deteriorating diabetic control associated with high-dose inhaled budesonide.

Authors:  J L Faul; L J Cormican; V J Tormey; W P Tormey; C M Burke
Journal:  Eur Respir J       Date:  1999-07       Impact factor: 16.671

2.  High dose inhaled corticosteroids and dose dependent loss of diabetic control.

Authors:  J L Faul; W Tormey; V Tormey; C Burke
Journal:  BMJ       Date:  1998-11-28

3.  Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital.

Authors:  H C Smyllie; C K Connolly
Journal:  Thorax       Date:  1968-11       Impact factor: 9.139

4.  When should hypertension be treated? The different perspectives of Canadian family physicians and patients.

Authors:  F A McAlister; A M O'Connor; G Wells; S A Grover; A Laupacis
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

5.  Information needed to decide about cardiovascular treatment in primary care.

Authors:  J Robson
Journal:  BMJ       Date:  1997-01-25

Review 6.  Post-transplant diabetes mellitus. The role of immunosuppression.

Authors:  R M Jindal; R A Sidner; M L Milgrom
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

7.  Incidence and prevalence of diabetes in Manitoba, 1986-1991.

Authors:  J F Blanchard; S Ludwig; A Wajda; H Dean; K Anderson; O Kendall; N Depew
Journal:  Diabetes Care       Date:  1996-08       Impact factor: 19.112

8.  Glucocorticoids and the risk for initiation of hypoglycemic therapy.

Authors:  J H Gurwitz; R L Bohn; R J Glynn; M Monane; H Mogun; J Avorn
Journal:  Arch Intern Med       Date:  1994-01-10

9.  Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy.

Authors:  H O Conn; T Poynard
Journal:  J Intern Med       Date:  1994-12       Impact factor: 8.989

10.  Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment?

Authors:  J E Hux; C D Naylor
Journal:  Med Decis Making       Date:  1995 Apr-Jun       Impact factor: 2.583

View more
  37 in total

Review 1.  Quantifying adverse drug events : are systematic reviews the answer?

Authors:  Mahyar Etminan; Bruce Carleton; Paula A Rochon
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 2.  Drug dosage in the elderly: dermatological drugs.

Authors:  Anna Flammiger; Howard Maibach
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease.

Authors:  Shail M Govani; Wyndy L Wiitala; Ryan W Stidham; Sameer D Saini; Jason K Hou; Linda A Feagins; Jeremy B Sussman; Peter D R Higgins; Akbar K Waljee
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

Review 4.  Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance.

Authors:  Felipe Vilaça Cavallari Machado; Fabio Pitta; Nidia Aparecida Hernandes; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2018-03-06       Impact factor: 3.633

Review 5.  Management issues with elderly-onset rheumatoid arthritis: an update.

Authors:  Ignazio Olivieri; Carlo Palazzi; Giovanni Peruz; Angela Padula
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

6.  Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Authors:  Erminia Ridolo; P Kihlgren; I Pellicelli; M C Nizi; F Pucciarini; C Incorvaia
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

7.  Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.

Authors:  Zurab Nadareishvili; Kaleb Michaud; John M Hallenbeck; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2008-08-15

8.  Sudden sensorineural hearing loss: systemic steroid therapy and the risk of glucocorticoid-induced hyperglycemia.

Authors:  Christian Rohrmeier; Nikola Koemm; Philipp Babilas; Philipp Prahs; Juergen Strutz; Roland Buettner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-28       Impact factor: 2.503

Review 9.  Elderly-onset sarcoidosis: prevalence, clinical course, and treatment.

Authors:  Yvan Jamilloux; Marc Bonnefoy; Dominique Valeyre; Loig Varron; Christiane Broussolle; Pascal Sève
Journal:  Drugs Aging       Date:  2013-12       Impact factor: 3.923

10.  Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands.

Authors:  Michiel W van der Linden; Fernie J A Penning-van Beest; Tamar Nijsten; Ron M C Herings
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.